AKRO logo

Akero Therapeutics, Inc. Common Stock


AKRO: Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.


Show AKRO Financials

Consumer Interest
SEC Filings

Recent trades of AKRO by members of U.S. Congress

Recently reported changes by institutional investors

Quiver Logo

No Whale Activity for this ticker

Institutional Holdings Dashboard

Quarterly net insider trading by AKRO's directors and management

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

Quiver Logo

No new patents for this ticker

U.S. Patents Dashboard
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of AKRO in WallStreetBets Daily Discussion


Recent insights relating to AKRO

CNBC Recommendations

Recent picks made for AKRO stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in AKRO

Corporate Flights

Flights by private jets registered to AKRO